Table 2.
Levels of SETD2 mRNA expression (After CK19 normalisation) in each group of patients
| Parameter | subgroups | No. | Median | Mean ± SD |
|---|---|---|---|---|
| All samples | SETD2 all tissue | 153 | 27 | 85547 ± 498012 |
| Normal tissue | 33 | 406 | 414434 ± 1106629 | |
| Tumor tissue | 120 | 17 | 20950 ± 37626 | |
| NPI | NPI1 | 68 | 11 | 8755 ± 26203 |
| NPI2 | 37 | 24 | 16517 ± 55868 | |
| NPI3 | 15 | 3 | 318 ± 645 | |
| Grade | Grade1 | 23 | 3 | 2592 ± 9686 |
| Grade2 | 41 | 19 | 11942 ± 35360 | |
| Grade3 | 56 | 26 | 11457 ± 44706 | |
| TNM staging | TNM1 | 69 | 4 | 8551 ± 29766 |
| TNM2 | 40 | 42 | 8578 ± 24043 | |
| TNM3 | 7 | 0 | 174 ± 414 | |
| TNM4 | 4 | 221 | 679 ± 1081 | |
| Clinical outcomes | Disease free | 81 | 13 | 12239 ± 43466 |
| Alive with Metastasis | 7 | 2 | 1983 ± 5142 | |
| Local recurrence | 5 | 930 | 3513 ± 5683 | |
| Died of Br Ca | 20 | 16 | 698 ± 1741 | |
| ER receptor status | ERą negative | 7 | 24 | 4742 ± 18706 |
| ERą positive | 26 | 41 | 14278 ± 46482 | |
| ERβ negative | 62 | 6 | 1698 ± 4441 | |
| ERβ positive | 17 | 27 | 13353 ± 43908 |